Related Experiment Video
Updated: Jul 17, 2026
Nasal Brushing Sampling and Processing Using Digital High Speed Ciliary Videomicroscopy – Adaptation for the COVID-19 Pandemic
Published on: November 7, 2020
Greater celandine (Chelidonium majus L.) for COVID-19: A twenty-case series
Nilo E Gardin1, Anne Jacqueline Braga1
1Associação Brasileira de Medicina Antroposófica (Brazilian Association of Anthroposophic Medicine), Belo Horizonte, Brazil.
Insights
Greater celandine (Chelidonium majus) showed promising results in treating mild COVID-19 symptoms in a small group of patients. Most participants experienced significant symptom relief within days, with no adverse events reported.
Area of Science:
- Phytomedicine
- Infectious Diseases
- Clinical Research
Background:
- The COVID-19 pandemic, caused by SARS-CoV-2, has led to a global health crisis with limited etiological treatments.
- Medicinal plants are increasingly explored for therapeutic potential against viral infections.
- Greater celandine (Chelidonium majus L.) has traditional uses but its efficacy against COVID-19 is uninvestigated.
Purpose of the Study:
- To describe the clinical evolution of COVID-19 outpatients treated with Greater celandine.
- To evaluate the safety and preliminary efficacy of Chelidonium majus in managing mild COVID-19 symptoms.
Main Methods:
- A case series of 20 consecutive COVID-19 outpatients treated with Chelidonium majus 10% mother tincture.
- Dosage: 20-30 drops, three times daily for 3-12 days (median 5 days).
- Clinical features and evolution were monitored during and after treatment.
Main Results:
- All 20 patients experienced complete or near-complete clinical improvement within 1-9 days (median 3 days).
- Common COVID-19 symptoms like fever, fatigue, cough, and anosmia resolved.
- No adverse events were reported during the treatment period.
Conclusions:
- Chelidonium majus demonstrated potential as a safe and effective treatment for mild COVID-19.
- This casuistry suggests further research into Chelidonium majus for COVID-19 treatment is warranted.
- The findings may encourage larger clinical trials to validate its therapeutic role.
Abstract:
In December 2019, an outbreak of coronavirus disease 2019 (COVID-19) occurred in Wuhan, China, with a rapid increase in cases worldwide. Until now, among several drugs tested, none demonstrated sufficient efficacy for its etiological treatment. Greater celandine (Chelidonium majus L.) is a well-known medicinal plant, traditionally indicated for digestive disorders and topically to remove warts. This study, performed at private offices in São Paulo and Aracaju (Brazil), describes 20 consecutive COVID-19 outpatients treated with greater celandine and their clinical evolution. The patients, aged 14-71 years (median of 41 years), were treated with Chelidonium majus 10% mother tincture, 20-30 drops three times a day for 3-12 days (median of 5 days). Clinical features were assessed during the treatment and at least until 1 week after its end. These cases were considered mild, as most COVID-19 cases. The symptoms were mainly fever, fatigue, cough, sore throat, coryza, anosmia, ageusia, and headache. Ten patients had comorbidities, such as hypertension, diabetes, and overweight. Complete or almost complete clinical improvement occurred within 1-9 days of treatment (median of 3 days). There were no adverse events. This casuistry, although small, may inspire other researchers to continue investigating Chelidonium majus as a healing treatment for COVID-19.
Related Concept Videos
01:25Cholera
01:29Coronavirus
01:20Cholecystitis